Immuno-oncology is a key area for biological drug development and activity has exploded over the past decade. Today, IO therapies represent a third of the biologics pipeline, and antibody development remains the focus.

The Swiss biotech has raised an impressive series A round which will go towards the development of T-cell engagers based on its unique technology, with an eye to reducing off-tumor activity.

The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.